AKBA

Akebia

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$269.3M

Burn Rate (Qtr)

$60M

Company Profile

Since our founding in 2007, we’ve put tenacity and innovation to work to develop novel therapeutics that have the potential to set new standards of care for people living with kidney disease. We have emerged as a leader with deep roots in the renal community. Today, we are a fully integrated biopharmaceutical company with both an experienced nephrology-focused commercial team and a robust development organization.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Auryxia (ferric citrate)

control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis AND treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis

Quarterly Sales (Approved)

February 24, 2021

Vadadustat (Inno2vate)

Anemia with Chronic Kidney Disease (CKD) undergoing dialysis

NDA Filing

2021

Vadadustat- PRO2TECT

Non-dialysis patients with anemia related CKD

NDA filing

2021

Vadadustat

Prevention and Treatment of ARDS in Patients Hospitalized with COVID-19

Phase 3

TBD

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon